SARS-CoV-2 vaccination response in people living with HIV
- Conditions
- COVID-19, HIV
- Registration Number
- NL-OMON26993
- Lead Sponsor
- OLVG, LUMC, Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 1000
Inclusion Criteria
18 years or older, confirmed HIV-infection, selected by national regulations for SARS-CoV-2 vaccination
Exclusion Criteria
none
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the humoral vaccine efficacy against SARS-CoV-2 in PLWHIV 2 weeks after the completed vaccination schedule (all participants)
- Secondary Outcome Measures
Name Time Method 1. To find factors associated with intensity of immune response and/or related adverse events (all participants)<br>2. To determine the humoral vaccine efficacy against SARS-CoV-2 in PLWHIV 3 weeks after the first vaccination (subgroup participants)<br>3. To measure anti-SARS-CoV-2 neutralising antibody response (subgroup participants)<br>4. To determine the duration of serologic anti-SARS-CoV-2 immune responses over time (all participants)<br>5. To evaluate anti-SARS-CoV-2 specific T-cell responses (subgroup participants)